Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. (Q46416585)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Valérie Bardet

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Nicolas Chapuis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Didier Bouscary

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Chadi Al-Nawakil

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Edward Bourry

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Christian Roux

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Sophie Park

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Sylvain Choquet

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

François Dreyfus

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

publication date

1 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

2012-2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

Genetic aberrations and survival in plasma cell leukemia

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190802290660

Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802290660

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802290660

Primary plasma cell leukaemia: a report of 18 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802290660

Stem-cell transplantation for multiple myeloma in the era of novel drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802290660

Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802290660

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802290660

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802290660

10.1080/10428190802290660

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18720213%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference